| You are here: Home: BCU 9|2004: Mark D Pegram, MD: Select publications
Select publications
Buzdar AU et al. Significantly higher pathological complete remission (PCR) rate following
neoadjuvant therapy with trastuzumab (H), paclitaxel (P), and anthracycline-containing chemotherapy
(CT): Initial results of a randomized trial in operable breast cancer (BC) with HER-2
positive disease. Proc ASCO 2004;Abstract 520.
Hurley J et al. Platinum salts and docetaxel as primary therapy of locally advanced and inflammatory
breast cancer: The final report of three sequential studies. Breast Cancer Res Treat 2003;Abstract 238.
Konecny G et al. Quantitative association between HER-2/neu and steroid hormone receptors in
hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95(2):142-53. Abstract
Pietras RJ. Antitumor therapy with Herceptin and Faslodex for dual targeting of HER-2 and
estrogen receptors in breast cancer with HER-2 overexpression. Presentation. San Antonio Breast
Cancer Symposium, 2003. Abstract
|
